Form 8-K - Current report:
SEC Accession No. 0000950170-22-004851
Filing Date
2022-03-29
Accepted
2022-03-29 07:41:56
Documents
14
Period of Report
2022-03-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K glue-20220329.htm   iXBRL 8-K 61049
2 EX-99.1 glue-ex99_1.htm EX-99.1 211853
3 GRAPHIC img106802192_0.jpg GRAPHIC 4656
  Complete submission text file 0000950170-22-004851.txt   405959

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT glue-20220329_lab.xml EX-101.LAB 17415
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT glue-20220329_pre.xml EX-101.PRE 11565
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT glue-20220329.xsd EX-101.SCH 2497
8 EXTRACTED XBRL INSTANCE DOCUMENT glue-20220329_htm.xml XML 4892
Mailing Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210
Business Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40522 | Film No.: 22777381
SIC: 2836 Biological Products, (No Diagnostic Substances)